DARZALEX

Product Overview

About DARZALEX

DARZALEX (daratumumab) is a prescription medicine used to treat adults with certain types of multiple myeloma. It is a monoclonal antibody that targets and binds to a protein called CD38 on the surface of cancer cells, helping to slow down or stop the growth of these cells.

Key Benefits & Uses

• Treatment of adults with multiple myeloma who have received at least one prior therapy, including those who have received lenalidomide and a proteasome inhibitor.
• Treatment of adults with multiple myeloma who have received at least two prior therapies, including those who have received lenalidomide and a proteasome inhibitor.
• Treatment of adults with multiple myeloma who have received at least three prior therapies, including those who have received lenalidomide and a proteasome inhibitor.

Active Ingredient & Action

DARZALEX (daratumumab) works by binding to CD38 on the surface of cancer cells, which helps to trigger a response from the immune system to attack and destroy these cells. This can help to slow down or stop the growth of cancer cells, leading to improved outcomes for patients with multiple myeloma.

Important Notes

It is essential to discuss the potential benefits and risks of DARZALEX with your doctor before starting treatment. DARZALEX can cause serious side effects, including infusion reactions, high blood pressure, and kidney damage. Your doctor will monitor you closely during treatment to minimize the risk of these side effects.